151 related articles for article (PubMed ID: 35969832)
1. Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018.
Berenson AB; Chang M; Hawk ET; Ramondetta LM; Hoang T
Cancer Prev Res (Phila); 2022 Nov; 15(11):777-784. PubMed ID: 35969832
[TBL] [Abstract][Full Text] [Related]
2. Update of HPV-associated female genital cancers in the United States, 1999-2004.
Watson M; Saraiya M; Wu X
J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
[TBL] [Abstract][Full Text] [Related]
3. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
[TBL] [Abstract][Full Text] [Related]
4. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.
Saraiya M; Watson M; Wu X; King JB; Chen VW; Smith JS; Giuliano AR
Cancer; 2008 Nov; 113(10 Suppl):2865-72. PubMed ID: 18980209
[TBL] [Abstract][Full Text] [Related]
5. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
[TBL] [Abstract][Full Text] [Related]
6. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
8. Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001-2017.
Mix JM; Gopalani SV; Simko S; Saraiya M
Prev Med; 2022 Nov; 164():107302. PubMed ID: 36240909
[TBL] [Abstract][Full Text] [Related]
9. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
[TBL] [Abstract][Full Text] [Related]
10. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination.
Rasmussen CL; Thomsen LT; Aalborg GL; Kjaer SK
Gynecol Oncol; 2020 Jun; 157(3):664-670. PubMed ID: 32276790
[TBL] [Abstract][Full Text] [Related]
11. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors.
Balamurugan A; Ahmed F; Saraiya M; Kosary C; Schwenn M; Cokkinides V; Flowers L; Pollack LA
Cancer; 2008 Nov; 113(10 Suppl):2919-25. PubMed ID: 18980275
[TBL] [Abstract][Full Text] [Related]
12. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
13. Risk of human papillomavirus-associated cancers among persons with AIDS.
Chaturvedi AK; Madeleine MM; Biggar RJ; Engels EA
J Natl Cancer Inst; 2009 Aug; 101(16):1120-30. PubMed ID: 19648510
[TBL] [Abstract][Full Text] [Related]
14. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
15. Cancers attributable to human papillomavirus infection.
Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
[TBL] [Abstract][Full Text] [Related]
16. Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected Hispanics living in the United States.
Ortiz AP; Engels EA; Nogueras-González GM; Colón-López V; Soto-Salgado M; Vargas A; Machin M; Shiels MS
Cancer; 2018 Dec; 124(23):4520-4528. PubMed ID: 30345506
[TBL] [Abstract][Full Text] [Related]
17. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
18. Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers.
Aninye IO; Berry-Lawhorn JM; Blumenthal P; Felder T; Jay N; Merrill J; Messman JB; Nielsen S; Perkins R; Rowen T; Saslow D; Trimble CL; Smith-McCune K
J Womens Health (Larchmt); 2021 Dec; 30(12):1667-1672. PubMed ID: 34871035
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
Dehlendorff C; Baandrup L; Kjaer SK
J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
